Bullseye Asset Management’s AbCellera Biologics ABCL Stock Holding History

Bullseye Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,766	Closed	-$134K	–	71
2023 Q1	$134K	Hold	17,766	–	–	0.07%	72
2022 Q4	$180K	Hold	17,766	–	–	0.1%	76
2022 Q3	$176K	Hold	17,766	–	–	0.1%	80
2022 Q2	$189K	Hold	17,766	–	–	0.11%	82
2022 Q1	$173K	Hold	17,766	–	–	0.08%	85
2021 Q4	$254K	Sell	17,766 -10,048	-36%	-$152K	0.1%	88
2021 Q3	$557K	Buy	27,814 +515	+2%	+$9.1K	0.19%	89
2021 Q2	$600K	Hold	27,299	–	–	0.2%	86
2021 Q1	$927K	Buy	27,299 +10,000	+58%	+$398K	0.35%	81
2020 Q4	$695K	Buy	+17,299	New	+$791K	0.26%	89

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Bullseye Asset Management's ABCL Position: Q2 2023 in Review

Bullseye Asset Management sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 17,766 shares — an estimated $134K sold.

Bullseye Asset Management first reported a position in ABCL in Q4 2020 and held it in 10 quarters. The position peaked at $927K in Q1 2021. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

Bullseye Asset Management reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
Bullseye Asset Management sold 17,766 AbCellera Biologics shares in Q2 2023, an estimated $134K.
Bullseye Asset Management first reported a position in AbCellera Biologics in Q4 2020 and held it in 10 quarters.
Bullseye Asset Management's AbCellera Biologics position peaked at $927K in Q1 2021.
169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Bullseye Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.